1300 South El Camino Real
Suite 400
San Mateo, CA 94402
United States
(650) 781-5200
https://www.kronosbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 61
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Norbert W. Bischofberger Ph.D. | President, CEO & Director | 912.2k | N/A | 1956 |
Mr. Joshua A. Kazam | Co-Founder & Director | 40k | N/A | 1977 |
Mr. David M. Tanen J.D. | Secretary & Director | 40k | N/A | 1971 |
Dr. Deborah A. Knobelman Ph.D. | COO & CFO | N/A | N/A | 1974 |
Dr. Margaux Bennett Ph.D. | Vice President of Corporate Development & Investor Relations | N/A | N/A | N/A |
Ms. Allison Frisbee J.D. | Senior Vice President of Corporate Operations & Legal | N/A | N/A | 1983 |
Dr. Charles Lin Ph.D. | Senior Vice President of Research & Development | N/A | N/A | 1985 |
Dr. Elizabeth A. Olek D.O., M.P.H. | Senior Vice President of Clinical Development | N/A | N/A | 1965 |
Mr. Wes Trotter Ph.D. | Senior Vice President of Drug Discovery & Pharmaceutical Development | N/A | N/A | N/A |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio, Inc.’s ISS governance QualityScore as of 1 June 2024 is 9. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 8; Compensation: 8.